✦ LIBER ✦

N6-isopentenyladenosine: A potential therapeutic agent for a variety of epithelial cancers

✍ Scribed by Monica Spinola; Francesca Colombo; F. Stefania Falvella; Tommaso A. Dragani

Publisher: John Wiley and Sons
Year: 2007
Tongue: French
Weight: 345 KB
Volume: 120
Category: Article
ISSN: 0020-7136
DOI: 10.1002/ijc.22601

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Isopentenyladenosine (i^6^A) is a product of isopentenyltransferases and, in mammals, occurs either bound to tRNA or as a free nucleoside. Sporadic reports have suggested an anticancer effect of i^6^A, mostly on leukemia cells. The present analysis of 9 human epithelial cancer cell lines derived from different types of malignant tissue revealed complete suppression of clonogenic activity in 8 of the lines after exposure to i^6^A at a concentration of 10 μM. Mechanistic studies showed that i^6^A tumor suppressor activity is associated with inhibition of cell proliferation, a block in DNA synthesis and morphological changes. These results point to i^6^A and to its possible derivatives as a new potential class of wide‐spectrum anticancer agents. © 2007 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Therapeutic potential of antisense Bcl-2

Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy

✍ Ryungsa Kim; Manabu Emi; Kazuaki Tanabe; Tetsuya Toge 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB

ChemInform Abstract: Endoxifen is a New

ChemInform Abstract: Endoxifen is a New Potent Inhibitor of PKC: A Potential Therapeutic Agent for Bipolar Disorder.

✍ Shoukath M. Ali; Ateeq Ahmad; Syed Shahabuddin; Moghis U. Ahmad; Saifuddin Sheik 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 21 KB 👁 1 views

Development of a hammerhead ribozyme aga

Development of a hammerhead ribozyme against bcl-2. I. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer

✍ Dorai, Thambi; Olsson, Carl A.; Katz, Aaron E.; Buttyan, Ralph 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 503 KB

## Background: The bcl-2 oncoprotein suppresses apoptosis and, when overexpressed in prostate cancer cells, makes these cells resistant to a variety of therapeutic agents, including hormonal ablation. therefore, bcl-2 provides a strategic target for the development of gene knockout therapies to tre

THERAPEUTIC STRATEGIES FOR THE INHIBITIO

THERAPEUTIC STRATEGIES FOR THE INHIBITION OF INDUCIBLE NITRIC OXIDE SYNTHASE—POTENTIAL FOR A NOVEL CLASS OF ANTI-INFLAMMATORY AGENTS

✍ JOSEF PFEILSCHIFTER; WOLFGANG EBERHARDT; RICHARD HUMMEL; DIETER KUNZ; HEIKO MÜHL 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 215 KB

In recent years, NO, a gas previously considered a potentially toxic chemical, has become established as a diffusible universal messenger mediating cell-cell communication throughout the body. In mammals, NO is a recognized mediator of blood vessel relaxation that helps to maintain blood pressure. I

ChemInform Abstract: Synthesis and Evalu

ChemInform Abstract: Synthesis and Evaluation of Novel N-Substituted-6-methoxynaphthalene-2-carboxamides as Potential Chemosensitizing Agents for Cancer.

✍ Tushar Narendra Lokhande; Chelakara Lakshmann Viswanathan; Aarti Shashikant Juve 📂 Article 📅 2008 🏛 John Wiley and Sons ⚖ 26 KB 👁 1 views

UDP-N-acetyl-D-galactosamine:polypeptide

UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6 (ppGalNAc-T6) mRNA as a potential new marker for detection of bone marrow-disseminated breast cancer cells

✍ Teresa Freire; Nora Berois; Cecilia Sóñora; Mario Varangot; Enrique Barrios; Edu 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 146 KB

## Abstract The evaluation of disseminated epithelial tumor cells in patients with early stages of breast cancer has generated considerable interest because of its potential association with poor clinical outcome. Considering that O‐glycosylation pathways are frequently altered in breast cancer, we